Revolution Medicines, Inc.
Revolution Medicines is a pioneering biotech company focused on developing targeted therapies for RAS-addicted cancers. Their mission is to revolutionize treatment through innovative, targeted medicines, with a focus on RAS(ON) inhibitors. They are committed to scientific excellence, patient-centricity, and fostering an inclusive, diverse culture. The company is engaged in cutting-edge research, clinical development, and supporting scientific advancement through funding and collaborations. They leverage a unique Tri-Complex Inhibitor Platform to target previously undruggable oncogenic proteins, especially RAS. Their pipeline includes investigational RAS(ON) inhibitors such as daraxonrasib, elironrasib, and zoldonrasib, with ongoing clinical trials targeting various RAS mutations in cancers like pancreatic, lung, and colorectal. They also explore expanding their platform to other frontier oncology targets.
Industries
Nr. of Employees
large (251-1000)
Revolution Medicines, Inc.
Patents
Products
Investigational RAS-targeted small-molecule inhibitors (clinical-stage)
A portfolio of investigational, orally administered small-molecule inhibitors designed to selectively target the active state of RAS proteins using tri-complex and structure-guided approaches; being evaluated as monotherapy and in combination in clinical trials for RAS-driven cancers.
Investigational RAS-targeted small-molecule inhibitors (clinical-stage)
A portfolio of investigational, orally administered small-molecule inhibitors designed to selectively target the active state of RAS proteins using tri-complex and structure-guided approaches; being evaluated as monotherapy and in combination in clinical trials for RAS-driven cancers.
Services
Acceptance and review of applications for independent medical education grants, externally sponsored research, sponsorships, and charitable donations; potential funding or provision of study drug for eligible investigator-initiated studies.
Partnerships and sponsorships to support scientific, medical, or healthcare education consistent with organizational policies, excluding promotional activities for products.
Access to research tool compounds for academic and non-profit investigators under a material transfer agreement for non-commercial research purposes.
Acceptance and review of applications for independent medical education grants, externally sponsored research, sponsorships, and charitable donations; potential funding or provision of study drug for eligible investigator-initiated studies.
Partnerships and sponsorships to support scientific, medical, or healthcare education consistent with organizational policies, excluding promotional activities for products.
Access to research tool compounds for academic and non-profit investigators under a material transfer agreement for non-commercial research purposes.
Expertise Areas
- Clinical trial management
- Translational research and preclinical pharmacology
- Small-molecule discovery and medicinal chemistry
- Structure-guided drug design
Key Technologies
- Chaperone-mediated tri-complex inhibitor approaches
- Structure-guided small-molecule design
- Covalent and noncovalent oral small-molecule inhibitors
- Next-generation sequencing (NGS) for tissue and ctDNA
News & Updates
A scientific presentation at The European Association for Cancer Research discussing a combination therapy approach to overcome resistance in KRAS G12C cancers.
A clinical trial comparing a RAS(ON) inhibitor to standard chemotherapy in pancreatic cancer.
Research showing how combination therapies can enhance immune response in RAS-driven cancers.
A study on resistance mechanisms and potential combination strategies in RAS mutant pancreatic cancer.
Research linking ctDNA reduction to clinical response in NSCLC.
A scientific article detailing the discovery of a G12V-selective RAS inhibitor.
A scientific presentation at The European Association for Cancer Research discussing a combination therapy approach to overcome resistance in KRAS G12C cancers.
A clinical trial comparing a RAS(ON) inhibitor to standard chemotherapy in pancreatic cancer.
Research showing how combination therapies can enhance immune response in RAS-driven cancers.
A study on resistance mechanisms and potential combination strategies in RAS mutant pancreatic cancer.
Research linking ctDNA reduction to clinical response in NSCLC.
A scientific article detailing the discovery of a G12V-selective RAS inhibitor.